Prosecution Insights
Last updated: November 04, 2026
Application No. 18/950,905

TABLETED EFFERVESCING DENTAL TREATMENT COMPOSITION, AND METHODS

Non-Final OA §103§112
Filed
Nov 18, 2024
Priority
Nov 17, 2023 — provisional 63/600,121
Examiner
KWON, JOHN SEUNGJAI
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Teeth Tabs Pllc
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
1y 6m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
53 granted / 120 resolved
-15.8% vs TC avg
Strong +21% interview lift
Without
With
+21.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
41 currently pending
Career history
166
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
69.1%
+29.1% vs TC avg
§102
12.7%
-27.3% vs TC avg
§112
12.9%
-27.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 120 resolved cases

Office Action

§103 §112
DETAILED ACTION Claims 1-7 are pending in the instant application. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application claims priority to the U.S. Provisional Application Serial No. 63/600,121 filed 11/17/2023. Claim Objections Claims 2-4 are objected to because of the following informalities: “tabletted” should be corrected to “tableted”. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 and 5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 and 5 blur the metes and bounds of the claims due to words in parentheses. The examiner cannot determine if they are exemplary or limited to one or more of these terms. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over Pesaro et al. (WO 2020/043269 A1), Dussia et al. (WO 2009/052421 A1), Figueiredo et al. (Propolis, Aloe Vera, Green Tea, Cranberry, Calendula, Myrrha, and Salvia Properties against Periodontal Microorganisms, microorganisms, 2022), and Tiftikci et al. (WO 2022/108546 A1). Pesaro discloses antimicrobial mixtures (Abstract). The formulation can be an effervescent preparation ([0083]). The composition can contain oils ([0028]), aloe vera ([0067]), shitake mushroom extract ([0063]), and green tea ([0062]). The preparation can be in the form of tablets ([0137]). Pesaro does not teach cranberry used for dental treatment. Dussia discloses compositions for administering an active ingredient orally or transmucosally having a film layer. The composition includes an effervescent compound (Abstract). An effervescent compound may include citric, tartaric and sodium bicarbonate ([0106]). The composition includes oil ([0109]), starches (corn, potato, rice, or tapioca) ([0093]), aloe vera ([0076]), shitake extract ([0058]), cranberry (claim 17). Cranberry is used to prevent or treat dental decay ([0065]). The composition can be in the form of a powder ([0004]). Dussia discloses that the film strip rapidly dissolved upon administration to the oral cavity ([0107]). Figueiredo discloses that natural agent is aloe vera or Aloe barbadensis, which is a cactus-like succulent plant that belongs to the Liliaceae family. Cosmetic and medicinal products are made from the mucilaginous tissue in the center of the aloe vera leaf. Aloe vera is known to have several therapeutic benefits and has long been used as a remedy for various conditions such as sunburn, wounds, skin problems and digestive tract disorders. The pharmacological benefits of aloe vera are attributed to its wound-healing effects; immunomodulatory activity; and anti-inflammatory, antioxidant and antimicrobial properties (pg 6, 2nd paragraph). Green tea has been shown to combat microorganisms in various ways, directly and indirectly, and has worked synergistically with some antibiotic agents. Its anti-inflammatory and antioxidant effects may also contribute to the antimicrobial effect (pg 7, 1st paragraph). Cranberries are among some foods that contain type A proanthocyanidins, which have higher bioactivity compared to type B. Cranberry bioactive agents have unique characteristics, and modern science is trying to identify the connections between the health benefits and the specific compounds that this fruit has. Particularly in dentistry, proanthocyanidins are known to inhibit oral biofilm adherence and for their anti-inflammatory effect that could potentially be able to neutralize the destructive inflammatory response of macrophages (pg 7, 3rd paragraph). Tiftikci discloses development of dental cleaning formulation in the form of effervescent tablet (Abstract). The production process generally includes the process of weighing each ingredient, passing each ingredient through a sieve, mixing ingredients, and pressing tablets (pg 6). Therefore, it would have been obvious to one of ordinary person in the art before the effective filing date of the claimed invention to have combined teachings of above to create a tableted effervescing dental treatment composition. This is taking some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Regarding claim 2, powder is taught above. regarding claim 3, oral cavity disintegration is taught above. Regarding claim 4, Tiftikci discloses that tablets weighed 450 mg on average. However, one of ordinary skill in the art would experiment with different tablet weights for consumers. Regarding claim 5, a method of producing an effervescent tablet is taught above. Regarding claim 6, Tiftikci discloses that the products can be easily transported due to different packaging sizes (pg 3, line 17). Regarding claim 7, it would be obvious to one of ordinary skill in the art to have provided a composition comprising ingredients beneficial for dental treatment, for treating dental surfaces simultaneously reducing dental plaque. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN SEUNGJAI KWON whose telephone number is (571)272-7737. The examiner can normally be reached Mon - Fri 8:00 - 5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A. Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN SEUNGJAI KWON/Examiner, Art Unit 1615 /Robert A Wax/Supervisory Patent Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Nov 18, 2024
Application Filed
Aug 07, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778891
MULTI-PEG LIPID COMPOUNDS
5y 6m to grant Granted Nov 03, 2026
Patent 12778902
FORMULATIONS COMPRISING A THERAPEUTIC PROTEIN AND AT LEAST ONE STABILIZER
3y 1m to grant Granted Nov 03, 2026
Patent 12734163
PHARMACEUTICAL PREPARATION AND METHOD FOR PRODUCING THE SAME
4y 10m to grant Granted Sep 15, 2026
Patent 12653793
Tellurium Nanostructures with Antimicrobial and Anticancer Properties Synthesized by Aloe Vera-Mediated Green Chemistry
4y 11m to grant Granted Jun 16, 2026
Patent 12648906
FAT EMULSION DIALYSATE, AND PREPARATION METHOD AND USE THEREOF
2y 11m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
65%
With Interview (+21.1%)
3y 6m (~1y 6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 120 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month